CA2527186A1 - Compositions comprising gastrin compounds and their use in diabetes - Google Patents

Compositions comprising gastrin compounds and their use in diabetes Download PDF

Info

Publication number
CA2527186A1
CA2527186A1 CA002527186A CA2527186A CA2527186A1 CA 2527186 A1 CA2527186 A1 CA 2527186A1 CA 002527186 A CA002527186 A CA 002527186A CA 2527186 A CA2527186 A CA 2527186A CA 2527186 A1 CA2527186 A1 CA 2527186A1
Authority
CA
Canada
Prior art keywords
composition
weeks
cells
gastrin compound
gastrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002527186A
Other languages
English (en)
French (fr)
Inventor
Antonio Cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waratah Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/016660 external-priority patent/WO2003100024A2/en
Application filed by Individual filed Critical Individual
Publication of CA2527186A1 publication Critical patent/CA2527186A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002527186A 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes Abandoned CA2527186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US03/16660 2003-05-27
PCT/US2003/016660 WO2003100024A2 (en) 2002-05-24 2003-05-27 Treatment for diabetes
PCT/CA2004/000769 WO2004105780A2 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes

Publications (1)

Publication Number Publication Date
CA2527186A1 true CA2527186A1 (en) 2004-12-09

Family

ID=33488788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002527186A Abandoned CA2527186A1 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes

Country Status (11)

Country Link
EP (1) EP1648495A2 (zh)
JP (1) JP2007513059A (zh)
CN (1) CN1829528A (zh)
AU (1) AU2004243541A1 (zh)
BR (1) BRPI0410710A (zh)
CA (1) CA2527186A1 (zh)
MX (1) MXPA05012605A (zh)
NO (1) NO20055582L (zh)
PL (1) PL379145A1 (zh)
RU (1) RU2005140518A (zh)
WO (1) WO2004105780A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040064605A (ko) 2001-01-12 2004-07-19 와라타 파마수티컬즈, 인크. 가스트린/ｃｃｋ 수용체 리간드 및 ｅｇｆ 수용체리간드를 함유하는, 섬 신생 유발을 위한 조성물
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
ATE445407T1 (de) 2002-06-07 2009-10-15 Waratah Pharmaceuticals Inc Methoden und kompositionen um diabetes zu behandeln
AU2005207870B2 (en) * 2004-01-30 2010-08-19 Waratah Pharmaceuticals, Inc. The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
WO2008106779A1 (en) * 2007-03-02 2008-09-12 Waratah Pharmaceuticals Inc. Gastrin compound for diabetes treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
JPH09511384A (ja) * 1994-01-24 1997-11-18 リサーチ トライアングル ファーマシューティカルズ リミテッド 若年型糖尿病の治療
KR20040064605A (ko) * 2001-01-12 2004-07-19 와라타 파마수티컬즈, 인크. 가스트린/ｃｃｋ 수용체 리간드 및 ｅｇｆ 수용체리간드를 함유하는, 섬 신생 유발을 위한 조성물
CA2501677A1 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes

Also Published As

Publication number Publication date
AU2004243541A1 (en) 2004-12-09
EP1648495A2 (en) 2006-04-26
WO2004105780A3 (en) 2005-01-20
BRPI0410710A (pt) 2006-06-13
PL379145A1 (pl) 2006-07-24
NO20055582D0 (no) 2005-11-25
CN1829528A (zh) 2006-09-06
RU2005140518A (ru) 2007-07-10
NO20055582L (no) 2006-02-27
JP2007513059A (ja) 2007-05-24
WO2004105780A2 (en) 2004-12-09
MXPA05012605A (es) 2006-02-22

Similar Documents

Publication Publication Date Title
AU2005207870B2 (en) The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
KR100365606B1 (ko) 수술후 이화작용 변화를 제거하기 위한 글루카곤-유사 펩타이드-1 (ｇｌｐ-1) 또는 동족체를 포함하는 약제학적 조성물
US20140364362A1 (en) Therapeutic agents comprising insulin amino acid sequences
US20090117102A1 (en) Methods and compositions using CD3 agonists
EP2186824A2 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
UA65549C2 (uk) Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU2002239384A1 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
NZ588857A (en) Isoform-specific insulin analogue for control blood sugar levels
CA2452044A1 (en) Pre-mixes of glp-1 and basal insulin
US20150361154A1 (en) Therapeutic agents, compositions, and methods for glycemic control
CN102421796A (zh) 新型Exendin变体及其缀合物
CZ299059B6 (cs) Použití GLP-1 nebo jeho analogu pro lécbu infarktu myokardu
WO2007095737A1 (en) Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
US20090156494A1 (en) Compositions and methods comprising gastrin compounds
EP1620464A1 (en) Combined use of keratinocyte growth factor agonists and gastrin compounds
CA2527186A1 (en) Compositions comprising gastrin compounds and their use in diabetes
US20100256061A1 (en) Gastrin compound for diabetes treatment
KR20060017617A (ko) 가스트린 화합물을 포함하는 조성물 및 이의 용도
TW201441253A (zh) 具有ｎ端電荷修飾之促胰島素肽衍生物
MXPA01003008A (es) Uso de peptido similar a glucagon 1 (glp-1) o analogos en el tratamiento de la crisis fulminante
MXPA99001871A (en) Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery
PL191627B1 (pl) Zastosowanie peptydu GLP-1 do wytwarzania leku do leczniczego zmniejszania masy ciała u człowieka

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20100527